Clinical Trial Update: ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating givosiran (ALN-AS1) for acute hepatic porphyrias has been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ala Dehydratase Deficiency Porphyria
• Hepatic Porphyrias
• Hereditary Coproporphyria
• Intermittent Porphyria
• Variegate Porphyria

Drugs mentioned

• givosiran (givosiran)

Snippet

Sponsor: Alnylam Pharmaceuticals | Conditions: Acute Hepatic Porphyria, Acute Intermittent Porphyria | Phase 3 | Status: COMPLETED | Results posted: 2020-02-11